• PacBio's management commentary attributed third-quarter 2026 revenue growth of 6% to $40.6 million to stronger instrument sales.
• Instrument revenue rose 16% to $13.2 million, driven by strong Revio placements in EMEA and higher Vega shipments despite Americas spending constraints.
• Consumables revenue fell to $20.8 million from $21.3 million as customers used existing reagent inventories and transitioned to multi-use workflows.
• Non-GAAP gross margin declined to 36% from 42%, reflecting higher memory costs and Vega manufacturing transition costs.
• Non-GAAP operating expenses decreased 13% to $47 million, reflecting continued expense discipline while maintaining investment in strategic priorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.